Compare · KRRO vs NVO
KRRO vs NVO
Side-by-side comparison of Korro Bio Inc. (KRRO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KRRO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.82B, about 1240.6x KRRO ($154.6M).
- Over the past year, KRRO is down 26.3% and NVO is down 44.8% - KRRO leads by 18.6 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 7 for KRRO).
- Both have 25 recent analyst ratings on file.
- Company
- Korro Bio Inc.
- Novo Nordisk A/S
- Price
- $10.97+1.39%
- $41.56-3.20%
- Market cap
- $154.6M
- $191.82B
- 1M return
- -14.30%
- -9.08%
- 1Y return
- -26.25%
- -44.83%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2019
- News (4w)
- 7
- 8
- Recent ratings
- 25
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KRRO
- President and CEO Aiyar Ram sold $196,673 worth of shares (15,152 units at $12.98), decreasing direct ownership by 17% to 74,848 units (SEC Form 4) to satisfy withholding tax
- Director Formela Jean Francois sold $39,897 worth of shares (2,860 units at $13.95) as part of a pre-agreed trading plan (SEC Form 4)
- President and CEO Aiyar Ram was granted 50,000 shares, increasing direct ownership by 125% to 90,000 units (SEC Form 4)
- Korro to Present at the 2026 Jefferies Global Healthcare Conference
- Korro Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
- Citigroup initiated coverage on Korro Bio with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Korro Bio Inc.
- Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 424B3 filed by Korro Bio Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care